Status:
COMPLETED
Hemodynamic Characteristics of Patients With SARS-CoV-2
Lead Sponsor:
Bicetre Hospital
Conditions:
Coronavirus
SARS-CoV-2
Eligibility:
All Genders
Brief Summary
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospita...
Detailed Description
The outbreak of COVID-19 is a worldwide concern. To our knowledge, the details of the hemodynamic characteristics of COVID-19 patients have not yet been well described. Besides, the cardiac injury was...
Eligibility Criteria
Inclusion
- Confirmed or suspected SARS-Cov2 cases
- Patients admitted to ICU, defined as a unit in which patients can receive vasopressors.
- Monitored by a transpulmonary thermodilution system (PiCCO2 (Pulsion Medical Systems, Feldkirchen, Germany) or EV1000 (Edwards Lifesciences, Irvine, United States of America).
Exclusion
- SARS Cov-2 Negative
- Refusal to participate in the study
Key Trial Info
Start Date :
March 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04337983
Start Date
March 13 2020
End Date
November 30 2020
Last Update
September 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bicetre Hospital
Paris, Val-de-Marne, France, 94270